Association of sorting and assembly machinery component 50 homolog gene polymorphisms with nonalcoholic fatty liver disease susceptibility

Ming Qiao, PhD a, Jian-hua Yang, PhD a, Yi Zhu, BA a, Jun-ping Hu, PhD b,*

Abstract

Background: Sorting and assembly machinery component 50 homolog (SAMM50) gene single-nucleotide polymorphisms (SNPs) have been connected with the susceptibility of nonalcoholic fatty liver disease (NAFLD), but with inconsistent results across the current evidence. The present work was schemed to explore the association between SAMM50 gene SNPs and NAFLD vulnerability via meta-analysis.

Methods: PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), and Wanfang were retrieved for eligible literature previous to June 10, 2021. The odds ratios (ORs) of the dichotomic variables and the standardized mean difference of quantitative variables with corresponding 95% confidence intervals (95% CIs) were computed to evaluate the strength of the associations. The quality of included studies was assessed using Newcastle-Ottawa Scale (NOS).

Results: In total, 8 case-control studies encompassing 8297 NAFLD patients and 7306 disease-free controls in this meta-analysis. Ultimately, this analysis included 8, 6, and 5 studies for rs2143571, rs3761472, and rs738491 polymorphisms respectively. The pooled data revealed that the 3 polymorphisms had conspicuous associations with NAFLD susceptibility: rs2143571, A vs. G, OR=1.51, 95% CI, 1.37–1.66, P < .01; rs3761472, A vs. G, OR=1.50, 95% CI, 1.35–1.67, P < .01; rs738491, A vs. G, OR=1.51, 95% CI, 1.40–1.63, P < .01.

Conclusion: This meta-analysis suggests that rs2143571, rs3761472, and rs738491 polymorphisms of the SAMM50 gene are appreciably associated with augmented risk of NAFLD vulnerability. It will provide the latest evidence to support the susceptibility of SAMM50 gene polymorphisms and NAFLD, and provide strategies for the prevention and treatment of NAFLD.

Abbreviations: 95% CIs = 95% confidence intervals, CNKI = China National Knowledge Infrastructure, GWAS = genome-wide association studies, HWE = Hardy–Weinberg equilibrium, NAFLD = nonalcoholic fatty liver disease, NAFLD = nonalcoholic fatty liver disease, NASH = nonalcoholic steatohepatitis, NOS = Newcastle–Ottawa Scale, ORs = odds ratios, SAMM50 = sorting and assembly machinery component 50 homolog, SNPs = gene single-nucleotide polymorphisms.

Keywords: gene polymorphism, meta-analysis, nonalcoholic fatty liver disease, SAMM50

1. Introduction

Nonalcoholic fatty liver disease (NAFLD) is an assessment of fatty infiltration in the liver by histopathologic examination in the absence of excessive alcohol intake, autoimmune, viral infection, or drug-induced liver disease.[1] It is gradually considered the liver disease component of metabolic syndrome, which is a complicated metabolic process in which both environmental and genetic factors are etiology.[2–4] The global burden of NAFLD is rapidly increasing and is expected to become the most common indication for liver transplantation with the alarming rise in the prevalence of obesity and metabolic syndrome.[5] According to the World Gastroenterology Organization, NAFLD has been increasing during the past 20 years and is now one of the most common types of liver disease in Western countries.[6] According to the present data, NAFLD affects 10%–30% of the general population in various countries, which has been viewed as a huge global health burden.[7,8]

Little is known about the latent mechanism involved in the development and pathogenesis of NAFLD, and yet it is a complicated metabolic process in which both environmental and genetic factors are etiology.[9] At present, genome-wide association studies (GWAS) have demonstrated several conspicuous genetic susceptibility genes such as PNPLA3, SAMM50, PARVB, APOC3, PPAR-γ, NCANCIILP2, FABP1, AGTR1, GSTs, which had been verified the crucial roles in the disease
onset and progression of NAFLD. Among them, rs738491, rs2143571, and rs3761472 in the sorting and assembly machinery component 50 homolog (SAMM50) gene were demonstrated to be notably associated with NAFLD susceptibility.

Up to now, there have been several reports on SAMM50 gene SNPs and NAFLD susceptibility, but the results were inconsistent. Additionally, the real situation of the whole population cannot be reflected due to the limited sample size and regional and ethnic differences in the existing single studies. Therefore, a meta-analysis will be conducted on the existing research results to obtain more authentic and reliable results.

2. Materials and Methods

2.1. Literature collection

This study depended on previously published literature and public databases. Thus, this work does not need ethical approval and patient consent. Two independent researchers searched the PubMed, Web of Science, Cochrane Library, CNKI, and Wanfang databases before June 10, 2021. The searching strategy of PubMed was exhibited as follows: (“Nonalcoholic fatty liver disease [Mesh]” OR Non-alcoholic fatty liver disease OR NAFLD OR Non-alcoholic steatohepatitis OR NASHi) AND (“Sorting and assembly machinery component 50 homolog” [Mesh] OR SAMM50) AND (“Single Nucleotide Polymorphism” [Mesh] OR Variant OR SNP OR Non-alcoholic fatty liver disease OR NAFLD OR NAFLD susceptibility. Cochran’s Q-test and I² test were applied to appraise the between-study heterogeneity. The random-effect model was employed to calculate merged ORs if $P < .1$, $I^2 > 50\%$. If not, the fixed-effect model was utilized for data synthesis. Sensitivity analysis was performed as well to assess the stability of all incorporated studies via the leave-one-out method. When the included studies were more than 10, a funnel plot was employed to evaluate the publication bias. On the contrary, less than 10 studies are not required. All analyses were done using Review Manager 5.3 software (Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen, Sweden).

2.2. Inclusion and exclusion criteria

Original studies were incorporated into this analysis in the light of the following inclusion criteria: (i) case-control studies; (ii) study investigated the associations of SAMM50 polymorphisms and NAFLD predisposition; (iii) NAFLD is diagnosed by pathology or ultrasound; (iv) control subjects were disease-free individuals; (v) detailed genotype data can be calculated for ORs and 95% CIs. Criteria for exclusion criteria were as follows: reviews, conference abstracts, commentary articles, letters to the editor, animal studies, unpublished data, case reports, and secondary causes of steatosis, including alcoholism, total parenteral nutrition, hepatitis B/C virus infection, and drug usage.

2.3. Methodological quality assessment

The Newcastle–Ottawa Scale (NOS) was performed to evaluate the methodological quality of included studies by 2 independent investigators. The NOS is composed of 3 aspects, namely selection, comparability, and exposure. Each study could receive 0 to 9 scores. Nevertheless, studies with ≥6 scores were regarded as high-quality studies. Disagreement was resolved by discussion.

2.4. Data extraction

The extracted information contained the name of the first author, year of publication, country, ethnicity, numbers of NAFLD and control subjects, diagnostic methods of NAFLD, genotype frequencies, and Hardy–Weinberg equilibrium (HWE) results. Two investigators extracted the information independently.

2.5. Statistical analysis

In the case of polymorphism with 2 alleles (A1 and A2), both the NAFLD and disease-free participants could be classified into 4 exposure groups (A1, A1A1, A1A2, or A2A2). Because the underlying genetic model for SAMM50 gene polymorphisms and NAFLD was unclear, the estimation of the association was based on 5 genetic models including allele contrast (A1 vs. A2), homozygous contrast (A1A1 vs. A2A2), heterozygous contrast (A1A2 vs. A2A2), dominant contrast (A1A1 + A1A2 vs. A2A2), and recessive contrast (A1A1 vs. A1A2 + A2A2). The control participants of incorporated studies were estimated via HWE. Summary ORs with 95% CIs were computed to specifically evaluate the relationship between SAMM50 gene polymorphisms and NAFLD susceptibility. Cochran’s Q-test and I² test were applied to appraise the between-study heterogeneity. The random-effect model was employed to calculate merged ORs if $P < .1$, $I^2 > 50\%$. If not, the fixed-effect model was utilized for data synthesis. Sensitivity analysis was performed as well to assess the stability of all incorporated studies via the leave-one-out method. When the included studies were more than 10, a funnel plot was employed to evaluate the publication bias. On the contrary, less than 10 studies are not required. All analyses were done using Review Manager 5.3 software (Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen, Sweden).

3. Results

3.1. Literature search

A primary search of electronic databases retrieved 26 potentially relevant publications: 13 from PubMed, 12 from Web of Science, 0 from Cochrane Library, 0 from CNKI, and 1 from Wanfang. No additional records were acquired from other sources. And then 20 studies remained after removing duplicated articles. Subsequently, a total of 4 irrelevant articles were excluded based on titles and abstracts screening. After applying inclusion and exclusion criteria, 3 unrelated articles (not related to NAFLD/SAMM50 gene polymorphisms), and 3 reviews were removed and 2 full-text article was not available. Ultimately, 8 studies (Kawaguchi et al., 2012; Kitamoto et al., 2013; Kitamoto et al., 2014; Kanth et al., 2014; Chen et al., 2015; Edelman et al., 2015; Larrieta et al., 2015; Chung et al., 2018) went into the process of meta-analysis. Overall, a flowchart summarizing the procedure of literature identification was illustrated in Figure 1.

3.2. Main characteristics

The studies were performed in Japan, India, China, USA, Mexico, and Korea. They were all case-control designed and published between 2012 and 2018. It is worth noting that 2 studies (Kitamoto et al., 2013; Chung et al., 2018) were genome-wide association studies (GWAS), including 2 stages: discovery I and validation II. In total, 8 studies encompassing 6297 cases and 7306 control participants were analyzed in the current analysis. For rs2143571, rs3761472, and rs738491 polymorphisms, there were 8, 6, and 5 studies ultimately incorporated, respectively. The main characteristics of the included literature were shown in Table 1. It should be noted that the study of Chung et al. (2018) did not provide the genotype frequency of the control group, so HWE could not be calculated. Studies with <6 scores were regarded as high-quality studies according to the evaluation of methodological quality (Table 2).

3.3. Rs2143571 polymorphism and NAFLD susceptibility

In a total of 8 studies (Kawaguchi et al., 2012; Kitamoto et al., 2013; Kitamoto et al., 2014; Kanth et al., 2014; Chen et al., 2015; Edelman et al., 2015; Larrieta et al., 2015; Chung et al., 2018) including 6297 NAFLD patients and 7306 controls for rs2143571 polymorphism. The allelic model was analyzed using the random-effect model due to significant heterogeneity. No remarkable heterogeneity was found in other genetic models, and a fixed-effect model was employed for data analysis. The results indicated that rs2143571 polymorphism was significantly
associated with NAFLD susceptibility under the allelic model (A vs. G, OR=1.51, 95% CI, 1.37–1.66, \( P < .01 \)), homozygous model (AA vs. GG, OR=2.61, 95% CI, 2.20–3.10, \( P < .01 \)), heterozygous model (AG vs. GG, OR=1.51, 95% CI, 1.37–1.66, \( P < .01 \)), dominant model (AA+AG vs. GG, OR=2.57, 95% CI, 2.20–3.10, \( P < .01 \)), and recessive model (AA vs. AG+GG, OR=1.99, 95% CI, 1.73–2.29, \( P < .01 \)) (Table 3). Carriers of the A-allele have a higher risk of NAFLD, as shown in Figure 2.

3.4. Rs3761472 polymorphism and NAFLD susceptibility

Overall, 6 research containing 5964 NAFLD and 6702 healthy subjects for rs3761472 to perform data analysis. The allelic model was analyzed by a random-effect model owing to significant heterogeneity observed. As the heterogeneity of genetic models was not significant, the fixed-effect model was employed for data analysis. The pooled data indicated there was a noticeable association between rs3761472 polymorphism and NAFLD susceptibility under allelic model (A vs. G, OR=1.50, 95% CI, 1.35–1.67, \( P < .01 \)), homozygous model (AA vs. GG, OR=2.64, 95% CI, 2.20–3.16, \( P < .01 \)), heterozygous model (AG vs. GG, OR=1.55, 95% CI, 1.32–1.81, \( P < .01 \)), dominant model (AA+AG vs. GG, OR=1.85, 95% CI, 1.60–2.15, \( P < .01 \)), and recessive model (AA vs. AG+GG, OR=1.97, 95% CI, 1.71–2.28, \( P < .01 \)) (Table 3). Carriers of the A-allele have a higher risk of NAFLD, as shown in Figure 3.

3.5. Rs738491 polymorphism and NAFLD susceptibility

A total of 5 studies with 2150 cases and 4792 controls were used for data pooled. The fixed-effect model was employed for data analysis owing of the between-study heterogeneity was not significant. The results indicated an obvious association between rs738491 polymorphism and NAFLD susceptibility under allelic model (A vs. G, OR=1.51, 95% CI, 1.40–1.63, \( P < .01 \)), homozygous model (AA vs. GG, OR=2.31, 95% CI, 1.94–2.76, \( P < .01 \)), heterozygous model (AG vs. GG, OR=1.44, 95% CI, 1.23–1.70, \( P < .01 \)), dominant model (AA+AG vs. GG, OR=1.73, 95% CI, 1.48–2.02, \( P < .01 \)), and recessive model (AA vs. AG+GG, OR=1.79, 95% CI 1.57–2.03, \( P < .01 \)) (Table 3). Carriers of the A-allele have a higher risk of NAFLD, as shown in Figure 4.

3.6. Sensitivity analysis and publication bias

After the omission of an individual study, the recalculated \( P \) value, ORs, and 95% CIs did not change substantially. Therefore, the outcomes were considered to be statistically robust and reliable.
Despite the specific pathological mechanism of NAFLD still needs to be explored. Nevertheless, research increasingly revealed that genetic predisposition plays a crucial intrinsic role in the occurrence and development of NAFLD.\cite{29} In addition, SNPs in humans might be one of the critical steps to disclosing the genetic factor for NAFLD pathogenesis. In recent years, researchers have found that many gene polymorphisms are associated with NAFLD vulnerability through GWAS. Kawaguchi et al.\cite{21} were the first to find a significant association between SAMM50 gene polymorphisms and NAFLD susceptibility in the Japanese population via GWAS. Subsequently, the study was carried out by researchers from different countries, but the results were inconsistent. This inconsistency might be caused by factors like limited sample sizes, confounding factors, as well as clinical heterogeneity of NAFLD. Therefore, we collected the existing evidence and looked into the associations of SAMM50 gene SNPs and NAFLD vulnerability via meta-analysis, which could combine data from individual studies, examine and explain the heterogeneity, and increase the statistical power. In conclusion, the merged data suggested a significant correlation between rs2143571, rs3761472, and rs738491 polymorphisms of the SAMM50 gene and NAFLD vulnerability. Two large samples of GWAS were included in the original studies, with sufficient assurance to ensure the reliability of the study results. Of note, rigid methodological quality assessment, heterogeneity,

### Table 1

Main characteristics of the included studies.

| Study     | Year | Country | Ethnicity | Means of diagnosis | Sample size (case/control) | A1 | A1A1 | A1A2 | A2A2 | P_HWE |
|-----------|------|---------|-----------|-------------------|----------------------------|----|------|------|------|-------|
| **Rs2143571** |      |         |           |                   |                            |    |      |      |      |       |
| Kawaguchi | 2012 | Japan   | Asian     | Liver biopsy      | 529/932                    | 587 | 167  | 253  | 109  | 0.83  |
| Kitamoto I| 2013 | Japan   | Asian     | Liver biopsy      | 390/934                    | 433 | 124  | 185  | 81   | 0.53  |
| Kitamoto II| 2013 | Japan   | Asian     | Liver biopsy      | 172/1012                   | 192 | 53   | 86   | 33   | 0.13  |
| Kitamoto | 2014 | Japan   | Asian     | Liver biopsy      | 540/1012                   | 292 | NA   | NA   | NA   | 0.45  |
| Kanth     | 2014 | India   | Asian     | Liver biopsy      | 156/150                    | 97  | NA   | NA   | NA   | 0.60  |
| Chen      | 2015 | China   | Asian     | Ultrasound        | 340/452                    | 376 | 112  | 152  | 76   | 0.36  |
| Edelman   | 2015 | USA     | Caucasian | Liver biopsy      | 39/24                      | 34  | 9    | 16   | 14   | 0.22  |
| Larrieta  | 2015 | Mexico  | Caucasian | Ultrasound        | 178/453                    | 154 | 33   | 88   | 57   | 0.30  |
| Chung I   | 2018 | Korea   | Asian     | Ultrasound        | 2816/1593                  | 255 | NA   | NA   | NA   | 0.12  |
| Chung II  | 2018 | Korea   | Asian     | Ultrasound        | 1137/744                   | 1018| NA   | NA   | NA   | 0.56  |
| **Rs3761472** |      |         |           |                   |                            |    |      |      |      |       |
| Kawaguchi | 2012 | Japan   | Asian     | Liver biopsy      | 528/932                    | 582 | 162  | 258  | 108  | 0.81  |
| Kitamoto I| 2013 | Japan   | Asian     | Liver biopsy      | 392/934                    | 438 | 126  | 186  | 80   | 0.78  |
| Kitamoto II| 2013 | Japan   | Asian     | Liver biopsy      | 172/1011                   | 192 | 53   | 86   | 33   | 0.85  |
| Kitamoto | 2014 | Japan   | Asian     | Liver biopsy      | 540/1012                   | 292 | NA   | NA   | NA   | 0.42  |
| Chen      | 2015 | China   | Asian     | Ultrasound        | 340/452                    | 357 | 102  | 153  | 85   | 0.35  |
| Edelman   | 2015 | USA     | Caucasian | Liver biopsy      | 39/24                      | 30  | 8    | 14   | 17   | 0.80  |
| Chung I   | 2018 | Korea   | Asian     | Ultrasound        | 2816/1593                  | 2534| NA   | NA   | NA   | 0.12  |
| Chung II  | 2018 | Korea   | Asian     | Ultrasound        | 1137/744                   | 1026| NA   | NA   | NA   | 0.56  |
| **Rs738491** |      |         |           |                   |                            |    |      |      |      |       |
| Kawaguchi | 2012 | Japan   | Asian     | Liver biopsy      | 529/932                    | 667 | 214  | 239  | 76   | 0.10  |
| Kitamoto I| 2013 | Japan   | Asian     | Liver biopsy      | 392/934                    | 494 | 162  | 170  | 60   | 0.98  |
| Kitamoto II| 2013 | Japan   | Asian     | Liver biopsy      | 172/1011                   | 219 | 66   | 87   | 19   | 1.00  |
| Kitamoto | 2014 | Japan   | Asian     | Liver biopsy      | 540/1012                   | 335 | NA   | NA   | NA   | 0.49  |
| Chen      | 2015 | China   | Asian     | Ultrasound        | 340/452                    | 397 | 123  | 151  | 66   | 0.41  |
| Larrieta  | 2015 | Mexico  | Caucasian | Ultrasound        | 177/451                    | 161 | 38   | 85   | 54   | 0.33  |

A1/A2 = allelic gene; HWE = Hardy–Weinberg equilibrium; NA = not reported.

### Table 2

Quality assessment of included studies based upon the Newcastle–Ottawa Scale (NOS).

| Item/Study | Kawaguchi2012 | Kitamoto 2013 | Kitamoto 2014 | Kanth 2014 | Chen 2015 | Edelman 2015 | Larrieta 2018 | Chung 2018 |
|-----------|---------------|---------------|---------------|------------|------------|---------------|---------------|------------|
| Selection | Adequate definition of cases | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|           | Representativeness of cases | 1 | 1 | 1 | 1 | 0 | 0 | 1 |
|           | Selection of control subjects | 1 | 0 | 0 | 0 | 1 | 1 | 1 |
|           | Definition of control subjects | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|          | Comparable | | | | | | | |
| Exposure  | Control for important factor or additional factor | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exposure  | Exposure assessment | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exposure  | Same method of ascertainment for all subjects | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exposure  | Non-response rate | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|          | Total score | 8 | 7 | 7 | 7 | 6 | 6 | 8 |

The funnel plot for assessment of publication bias was not implemented on account of fewer than 10 research.

4. Discussion

Despite the specific pathological mechanism of NAFLD still needs to be explored. Nevertheless, research increasingly revealed that genetic predisposition plays a crucial intrinsic role in the occurrence and development of NAFLD.\cite{29} In addition, SNPs in humans might be one of the critical steps to disclosing the genetic factor for NAFLD pathogenesis. In recent years, researchers have found that many gene polymorphisms are associated with NAFLD vulnerability through GWAS. Kawaguchi et al.\cite{21} were the first to find a significant association between SAMM50 gene polymorphisms and NAFLD susceptibility in the Japanese population via GWAS. Subsequently, the study was carried out by researchers from different countries, but the results were inconsistent. This inconsistency might be caused by factors like limited sample sizes, confounding factors, as well as clinical heterogeneity of NAFLD. Therefore, we collected the existing evidence and looked into the associations of SAMM50 gene SNPs and NAFLD vulnerability via meta-analysis, which could combine data from individual studies, examine and explain the heterogeneity, and increase the statistical power. In conclusion, the merged data suggested a significant correlation between rs2143571, rs3761472, and rs738491 polymorphisms of the SAMM50 gene and NAFLD vulnerability. Two large samples of GWAS were included in the original studies, with sufficient assurance to ensure the reliability of the study results. Of note, rigid methodological quality assessment, heterogeneity,
and sensitivity analysis also ensured the robustness of the study results.

In a word, we performed a meta-analysis of 8 case-control studies that satisfied the inclusion criteria. It should be noted that the current comprehensive analysis was more necessary and meaningful owing to the conclusions of qualified case-control studies are conflicting and contradictory. This work demonstrated that carriers of the A-allele of rs2143571, rs3761472, and rs738491 in the SAMM50 gene have a higher risk of NAFLD. Namely, it has a significantly increased risk for NAFLD. Furthermore, the outcomes of the meta-analysis were considered to be statistically robust and reliable according to the sensitivity analysis.

Sam50 is a kind of β-barrel protein distributed in the mitochondrial membrane and encoded by the SAMM50 gene. It plays an important role in the formation of the mitochondrial crest, the assembly of the respiratory chain complex, and the maintenance of mitochondrial DNA stability. Studies have revealed that Sam50 reduction may lead to changes in mitochondrial shape and cristal morphology, and SAM50 consumption could affect the mitochondrial respiratory complexes. In addition, changes in the normal structure of mitochondria could lead to insulin resistance, which is an important pathophysiological process of NAFLD. All the above studies have indicated that the SAMM50 gene and its expression products play a crucial role in the development of NAFLD. According to the results of this meta-analysis, A allele of rs2143571, rs3761472, and rs738491 in the SAMM50 gene might be related to mitochondrial dysfunction and insulin resistance, leading to the NAFLD development.

Up to now, this is the first synthetical study on the relationship between SAMM50 gene SNPs and NAFLD vulnerability. There were several strengths in this study. First, to gather a maximum amount of relevant literature, a comprehensive search strategy was adopted to retrieve eligible studies in both English and Chinese databases. Besides, the methodological quality of studies was evaluated via NOS, which allowed for the judgment of the potential risk of bias. According to the NOS, all eligible studies were of high methodological quality. Furthermore, sensitivity analyses were carried out in this study, which guaranteed the reliability of the findings.

Nevertheless, there still existed several drawbacks that should be acknowledged. First, although liver biopsy was regarded as the gold standard for NAFLD diagnosis, not all studies were included liver biopsy because pathology was expensive and invasive. Second, the original studies included in this study were mainly conducted in Asian and North American populations, and the results cannot reflect the situation of other populations. Third, we ignored the synergistic effect of polymorphisms at other sites of NAFLD because only 3 loci in the SAMM50 gene were studied in association with susceptibility to NAFLD. Thus, interactions between these loci and genes may result in concealing or amplifying the actual function of individual loci or genes. Leave aside these drawbacks, this study is the first to provide more accurate and powerful evidence on the association between SAMM50 gene SNPs and NAFLD vulnerability. Nevertheless, there still existed several drawbacks that should be acknowledged. First, although liver biopsy was regarded as the gold standard for NAFLD diagnosis, not all studies were included liver biopsy because pathology was expensive and invasive. Second, the original studies included in this study were mainly conducted in Asian and North American populations, and the results cannot reflect the situation of other populations. Third, we ignored the synergistic effect of polymorphisms at other sites of NAFLD because only 3 loci in the SAMM50 gene were studied in association with susceptibility to NAFLD. Thus, interactions between these loci and genes may result in concealing or amplifying the actual function of individual loci or genes. Leave aside these drawbacks, this study is the first to provide more accurate and powerful evidence on the association between rs2143571, rs3761472, and rs738491 polymorphisms of the SAMM50 gene and NAFLD vulnerability.

5. Conclusion

This meta-analysis suggests that rs2143571, rs3761472, and rs738491 polymorphisms of the SAMM50 gene are appreciably associated with an augmented risk of NAFLD vulnerability. In summary, this study will provide the latest evidence to support the susceptibility of SAMM50 gene polymorphisms and NAFLD, and provide strategies for the prevention and treatment of NAFLD. Concerning the limitations of this study, it is necessary to confirm the present findings with complementary studies with a larger sample size.
Acknowledgments
The authors would like to thank all studies and their participants involved in this investigation.

Author contributions
Conceptualization: Ming Qiao.
Supervision: Jian-hua Yang, Jun-ping Hu.
Validation: Yi Zhu.
Writing—original draft: Ming Qiao.
Writing—review & editing: Jian-hua Yang, Jun-ping Hu.

References
[1] Kemmer N, Neff GW, Franco E, et al. Nonalcoholic fatty liver disease epidemic and its implications for liver transplantation. Transplantation. 2013;10:860–2.
[2] Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;2:547–55.
[3] Younossi ZM, Koenig A, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;1:73–84.
[4] Chung TH, Shim JY, Lee YJ. Nonalcoholic fatty liver disease as a risk factor for prolonged corrected QT interval in apparently healthy Korean women. J Gastrointest Liver. 2020;29:59–64.
[5] Weinfurtner K, Dodge JL, Yao F, et al. Effect of nonalcoholic fatty liver disease and metabolic risk factors on waitlist outcomes in patients with hepatocellular carcinoma. Transpl Direct. 2020b:6:605.
[6] Severson TJ, Besur S, Bonkovsky HL. Genetic factors that affect nonalcoholic fatty liver disease: a systematic clinical review. World J Gastroenterol. 2016;22:6:742.
[7] Meex R, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017;13:509.
[8] Wang C, Gong J, Hao W. Development of gene polymorphisms in meditators of nonalcoholic fatty liver disease. Biomed Rep. 2017;7:95.
[9] Haas JT, Francque S, Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016;78:181–205.
[10] Tang S, Zhang J, Mei TT, et al. Association of PNPLA3 rs738409 G/C gene polymorphism with nonalcoholic fatty liver disease in children: a meta-analysis. BMC Med Genet. 2020;21:163–72.
[11] Zhen Y, Wen J, Qin L, et al. PPARG gene Pro12Ala variant contributes to the development of non-alcoholic fatty liver in middle-aged and older Chinese population. Mol Cell Endocrinol. 2012;348:255–9.
[12] Peng XE, Wu YL, Lu QQ, et al. Two genetic variants in FABP1 and susceptibility to non-alcohol fatty liver disease in a Chinese population. J Gastrointest Liver. 2020;29:59–64.
[13] Liu Y, Lu LL, Yuan DX, et al. AGTR1 rs3772621 gene polymorphism increases the risk of nonalcoholic fatty liver disease patients suffering coronary artery disease in northern Chinese Han population. Lipids Health Dis. 2016;15:1–5.
[14] Kordi-Tamandani DM, Hashemi M, Birjandian E, et al. Lack of association of GSTT1 and GSTP1 genes methylation and their expression profiles with risk of NAFLD. J Gastrointest Liver. 2011;35:387–92.
[15] Wang J, Ye C, Fei S, et al. Association between APOC3 polymorphisms and non-alcoholic fatty liver disease: a meta-analysis. Afr Health Sci. 2020;20:1800–8.
[16] Kitamoto T, Kitamoto A, Ogawa Y, et al. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease. J Hepatol. 2015;63:494–502.
[17] Ryckman K, Williams SM. Calculation and use of the Hardy-Weinberg model in association studies. Current Protocols in Human Genetics 2008; Chapter 1, Unit 1.18.
[18] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Brit Med J. 2003;327:557–60.
[19] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.
[20] Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. Can Med Assoc J. 2007;176:1091–6.
[21] Kawaguchi T, Sumida Y, Umemura A, et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One. 2012;7:783–92.
[22] Kitamoto T, Kitamoto A, Yoneda M, et al. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet. 2013;132:783–92.
[23] Kitamoto T, Kitamoto A, Yoneda M, et al. Targeted next-generation sequencing and fine linkage disequilibrium mapping reveals association of PNPLA3 and PARVB with the severity of nonalcoholic fatty liver disease. J Hum Genetics. 2014;59:241–6.
[24] Kanth V, Sasikala M, Rao PN, et al. Pooled genetic analysis in ultrasound measured nonalcoholic fatty liver disease in Indian subjects: a pilot study. World J Hepatol. 2014;6:435–42.
[25] Chen L, Lin Z, Man J, et al. Genetic variants in the SAMM50 gene create susceptibility to nonalcoholic fatty liver disease in a Chinese Han population. Hep Mon. 2015;15:e31076.
[26] Edelman D, Kala H, Delio M, et al. Genetic analysis of nonalcoholic fatty liver disease within a Caribbean-Hispanic population. Mol Genet Genom Med. 2016;3:558–69.
[27] Larrieta-Carrasco E, Flores YN, Macias-Kauffer LR, et al. Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transamnase levels in an admixed Mexican population. Exp Mol Pathol. 2018;104:50–8.
[28] Chung GE, Lee Y, Yim JY, et al. Genetic polymorphisms of PNPLA3 and SAMM50 are associated with nonalcoholic fatty liver disease in a Korean population. Gut Liver. 2018;12:316–23.
[29] Lallukka S, Sevastianova K, Peritil J, et al. Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3. Diabetologia. 2013;56:886–92.
[30] Ott C, Ross K, Straub S, et al. Sam50 functions in mitochondrial intermembrane space bridging and biogenesis of respiratory complexes. Mol Cell Bio. 2012;32:1173–88.
[31] Ott C, Dorsch E, Fraunholz M, et al. Detailed analysis of the human mitochondrial contact site complex indicate a hierarchy of subunits. PLoS One. 2015;10:e0120213.
[32] Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005;307:384–7.
[33] Ma ZA, Zhao Z, Turk J, et al. Mitochondrial dysfunction and beta-cell failure in type 2 diabetes mellitus. Exp Diabetes Res. 2012;2012:703538.
[34] Rector RS, Thyfault JP, Uptergrove GM, et al. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol. 2010;52:727–36.
[35] Sanyal AL, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183–9.